Abstract

Suruchi Singh*, Pankaj Bhatt, Narjes Alfuraiji, Mahdi M. Thuwaini and Ali Esmail Al-Snafi

ABSTRACT

Many studies have approved that COVID-19 disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus-1(SARS-CoV-1), and has spread in epidemic from across the world today. Initially, they affect the upper respiratory tract, induce viral infection in the lungs, and cause severe pneumonia in COVID-19 infected patients. After their infected body, they show changes in the other biomarkers in the body and imbalance the body response studied by the pathophysiology of the virus. However, this infection starts comorbidity directly and indirectly in COVID-19 infected patients. During this period of infection, the immune system is also suppressed by the virus and initiates other diseases. In the study of current work, the authors focus on the cardiovascular comorbidity of COVID-19 in the current work. In the COVID-19 comorbidity study, the virus mainly affects patients with hypertension. The risk factor of comorbidity of hypertension and cardiovascular disorder is 30.7% and 11.9% with diabetes mellitus. In this study, we reveal the pathophysiology, treatment, and management of cardiovascular diseases, their risk factor, and the medicinal results of patients infected patients. SARS-CoV-2 primarily targets ACE-2 receptors because this virus receives this receptor as a host for the cellular entry of the virus in the body; this leads to down-regulation in the maintenance of BP, and the body suffers from multiorgan failure. Other diseases related to CVS like inflammatory cardiomyopathy, congestive heart failure, irregular heartbeat, embolism events, and coronary infarction, also affect its pathophysiology.